On September 26, Hangzhou Matridx Biotechnology Co., Ltd. (hereinafter referred to as Matridx) announced that it had completed a strategic investment of hundreds of millions of yuan.

Mesa Laboratories said on Tuesday that it has acquired mass spectrometry-based genetic analysis firm Agena Bioscience for $300 million in cash.

Life science company RareCyte said on Thursday that it completed $24 million in financing from both new and existing investors.

QIAGEN to join the DAX on September 20, 2021, the effective date for changes in index composition. QIAGEN to remain in TecDAX comprised of the 30 largest German technology sector companies.

As of the end of August 2021, the first-half reports of IVD-related listed companies have basically been released. 64 IVD-related listed companies have achieved steady growth in the first half of 2021, and more than 70% of companies have shown positive growth in net profits.

On July 28, 2021, Thermo Fisher Scientific announcing that it would invest in the construction of another brand-new factory under Thermo Fisher China manufacturing center in Suzhou High Tech Zone. The total investment is $50 million, which is expected to be completed and put into use in 2022.

On July 9th, Roche Diagnostics Asia-Pacific production base and R&D center built another new manufacturing building-System Reagent Manufacturing Base. It was officially completed in Suzhou Industrial Park. The total investment in the project is 390 million yuan.

On June 26, 2021, Shanghai, Sanyou Biopharmaceutical (Shanghai) Co., Ltd. announced the closing of series B financing. This financing round was co-led by LH Ventures and Montesy Investment and followed by Grand Mount Capital and Seeking Capital (an existing investor).

SpeeDx announced recentlythat it has raised a total of $15 million from a US investment group.The Sydney, Australia-based molecular diagnostics developer said it had raised up to $10 million in additional equity investment from US-based Nort

Thermo Fisher Scientific, the world leader in serving science, recently announced that it will be investing more than $50m (£39.8m) in its global bioproduction capabilities to provide additional capacity for manufacturing single-use bioproc